Literature DB >> 27473267

Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.

Sarah A Weiss1, Sung Won Han2, Kevin Lui3, Jeremy Tchack4, Richard Shapiro5, Russell Berman6, Judy Zhong7, Michelle Krogsgaard8, Iman Osman9, Farbod Darvishian10.   

Abstract

Tumor-infiltrating lymphocytes (TILs) in primary melanomas are thought to represent the host antitumor immune response, but controversy exists over whether TILs offer independent prognostication of survival. We studied a cohort of 1241 patients with primary melanoma to assess the association of absent, nonbrisk, and brisk TIL grade with survival outcomes. We tested whether quantitative TIL counts using immunohistochemical lymphocyte markers CD3, CD45, and FOXP3 add prognostic value to TIL grading compared with histology alone in 15% of the cohort. To assess for intergroup immunologic heterogeneity among TIL grades, we investigated differential expression of 594 immunoregulatory genes in 67 primary melanomas. On histologic evaluation of 1241 primary melanomas, TILs were graded as absent (n=388, 31%), nonbrisk (n=330, 27%), and brisk (n=523, 42%). Patients with brisk TILs had improved recurrence-free survival (P=.025) and overall survival (P=.006) compared with patients with nonbrisk and absent TILs, for which there were no differences in recurrence-free survival (P=.40) or overall survival (P=.41). TIL quantitation by immunohistochemistry did not improve prognostication compared with TIL grading on hematoxylin and eosin-stained sections. Melanomas with nonbrisk and absent TILs share similar immunoregulatory gene expression profiles. In contrast, melanomas with brisk TILs demonstrate upregulation of T-cell activation pathways and inhibition of upstream immune checkpoint regulators. The presence of TILs in primary melanomas represents a heterogeneous group, and caution in prognostic interpretation is warranted. Melanomas with brisk TILs are defined by an immunostimulatory gene expression profile and improved prognosis compared with melanomas with nonbrisk or absent TILs.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brisk; Host immune response; Melanoma; Prognosis; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27473267      PMCID: PMC5706446          DOI: 10.1016/j.humpath.2016.07.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

1.  Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model.

Authors:  Ralph J Tuthill; Joseph M Unger; P Y Liu; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Pathol       Date:  2002-10       Impact factor: 2.493

2.  Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.

Authors:  R L Barnhill; J A Fine; G C Roush; M Berwick
Journal:  Cancer       Date:  1996-08-01       Impact factor: 6.860

3.  Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.

Authors:  Nancy E Thomas; Klaus J Busam; Lynn From; Anne Kricker; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Pamela A Groben; Honglin Hao; Irene Orlow; Anne S Reiner; Li Luo; Susan Paine; David W Ollila; Homer Wilcox; Colin B Begg; Marianne Berwick
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

4.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

7.  Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.

Authors:  Rebecca C Taylor; Ami Patel; Katherine S Panageas; Klaus J Busam; Mary S Brady
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

8.  Prognostic significance of tumor infiltrating lymphocytes in melanoma.

Authors:  Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Am Surg       Date:  2011-02       Impact factor: 0.688

9.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

10.  Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.

Authors:  M Mandalà; G L Imberti; D Piazzalunga; M Belfiglio; R Labianca; M Barberis; L Marchesi; P Poletti; L Bonomi; L Novellino; K Di Biagio; A Milesi; U Guerra; C Tondini
Journal:  Eur J Cancer       Date:  2009-06-22       Impact factor: 9.162

View more
  30 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Genomic and transcriptional Profiling of tumor infiltrated CD8+ T cells revealed functional heterogeneity of antitumor immunity in hepatocellular carcinoma.

Authors:  Zhenli Li; Geng Chen; Zhixiong Cai; Xiuqing Dong; Liman Qiu; Haipo Xu; Yongyi Zeng; Xiaolong Liu; Jingfeng Liu
Journal:  Oncoimmunology       Date:  2018-11-10       Impact factor: 8.110

Review 3.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

4.  Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes.

Authors:  Max O Meneveau; Zeyad T Sahli; Kevin T Lynch; Ileana S Mauldin; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

Review 5.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

6.  Tumour-infiltrating lymphocyte and histological regression in primary melanoma.

Authors:  Simone Ribero; I Torres-Navarro; R Botella-Estrada
Journal:  Arch Dermatol Res       Date:  2020-05-07       Impact factor: 3.017

7.  Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.

Authors:  Bernice Y Yan; Sandra Garcet; Nicholas Gulati; Felix Kiecker; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Avner Shemer; Hiroshi Mitsui; James G Krueger
Journal:  Exp Dermatol       Date:  2018-12-21       Impact factor: 3.960

8.  Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Authors:  Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

9.  MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

Authors:  M W Rohaan; R Gomez-Eerland; J H van den Berg; M H Geukes Foppen; M van Zon; B Raud; I Jedema; S Scheij; R de Boer; N A M Bakker; D van den Broek; L M Pronk; L G Grijpink-Ongering; A Sari; R Kessels; M van den Haak; H A Mallo; M Karger; B A van de Wiel; C L Zuur; C W Duinkerken; F Lalezari; J V van Thienen; S Wilgenhof; C U Blank; J H Beijnen; B Nuijen; T N Schumacher; J B A G Haanen
Journal:  Immunooncol Technol       Date:  2022-06-18

10.  The Anti-Cancer Effects of a Zotarolimus and 5-Fluorouracil Combination Treatment on A549 Cell-Derived Tumors in BALB/c Nude Mice.

Authors:  Ching-Feng Wu; Ching-Yang Wu; Robin Y-Y Chiou; Wei-Cheng Yang; Chuen-Fu Lin; Chao-Min Wang; Po-Hsun Hou; Tzu-Chun Lin; Chan-Yen Kuo; Geng-Ruei Chang
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.